PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate

European Urology

Volumn 67, Issue 4, 2015, Pages 795-802

  Ferraldeschi, Roberta ^a   Nava Rodrigues, Daniel ^a   Riisnaes, Ruth ^a   Miranda, Susana ^a   Figueiredo, Ines ^a   Rescigno, Pasquale ^a   Ravi, Praful ^a   Pezaro, Carmel ^a   Omlin, Aurelius ^a   Lorente, David ^a   Zafeiriou, Zafeiris ^a   Mateo, Joaquin ^a   Altavilla, Amelia ^a   Sideris, Spyridon ^a   Bianchini, Diletta ^a   Grist, Emily ^a   Thway, Khin ^a   Perez Lopez, Raquel ^a   Tunariu, Nina ^a   Parker, Chris ^a   Dearnaley, David ^a   Reid, Alison ^a   Attard, Gerhardt ^a   De Bono, Johann ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone acetate; Immunohistochemistry; Prostate cancer; PTEN

Indexed keywords

ABIRATERONE ACETATE; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENERAL CONDITION DETERIORATION; HORMONE SENSITIVE PROSTATE CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC PROSTATE CANCER; NEEDLE BIOPSY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROTEIN DEPLETION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR BIOPSY; DISEASE FREE SURVIVAL; MALE; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ABIRATERONE ACETATE; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923185936     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.10.027     Document Type: Article

References (30)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
2. H. Beltran, and M.A. Rubin New strategies in prostate cancer: translating genomics into the clinic Clin Cancer Res 19 2013 517 523
3. J. Cuzick, Z.H. Yang, and G. Fisher Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer Br J Cancer 108 2013 2582 2589
4. M. Schmitz, G. Grignard, and C. Margue Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis Int J Cancer 120 2007 1284 1292
5. B.S. Carver, C. Chapinski, and J. Wongvipat Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
6. M. Yoshimoto, I.W. Cunha, and R.A. Coudry FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome Br J Cancer 97 2007 678 685
7. A.H. Reid, G. Attard, and L. Ambroisine Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 2010 678 684
8. T.L. Lotan, B. Gurel, and S. Sutcliffe PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
9. K.A. Leinonen, O.R. Saramaki, and B. Furusato Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer Cancer Epidemiol Biomarkers Prev 22 2013 2333 2344
10. M.E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W.R. Sellers Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Res 59 1999 4291 4296
11. L.M. Chow, and S.J. Baker PTEN function in normal and neoplastic growth Cancer Lett 241 2006 184 196
12. Q. Ma, W. Fu, and P. Li FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment Mol Endocrinol 23 2009 213 225
13. Y. Chen, P. Chi, and S. Rockowitz ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss Nat Med 19 2013 1023 1029
14. B. Nan, T. Snabboon, E. Unni, X.J. Yuan, Y.E. Whang, and M. Marcelli The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity J Mol Endocrinol 31 2003 169 183
15. A.H. Reid, G. Attard, and D. Brewer Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer Mod Pathol 25 2012 902 910
16. N.C. Correia, A. Girio, I. Antunes, L.R. Martins, and J.T. Barata The multiple layers of non-genetic regulation of PTEN tumor suppressor activity Eur J Cancer 50 2014 216 225
17. P.C. Verhagen, P.W. van Duijn, and K.G. Hermans The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion J Pathol 208 2006 699 707
18. B. Han, R. Mehra, and R.J. Lonigro Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression Mod Pathol 22 2009 1083 1093
19. Z. Sangale, C. Prass, and A. Carlson A robust immunohistochemical assay for detecting PTEN expression in human tumors Appl Immunohistochem Mol Morphol 19 2011 173 183
20. M. Yoshimoto, J.C. Cutz, and P.A. Nuin Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias Cancer Genet Cytogenet 169 2006 128 137
21. S.K. Sandhu, W.R. Schelman, and G. Wilding The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol 14 2013 882 892
22. H. Ishibashi, T. Suzuki, and S. Suzuki Sex steroid hormone receptors in human thymoma J Clin Endocrinol Metab 88 2003 2309 2317
23. G. Attard, J.F. Swennenhuis, and D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
24. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
25. P. Ravi, J. Mateo, and D. Lorente External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone Eur Urol 66 2014 8 11
26. C. Thomas, F. Lamoureux, and C. Crafter Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo Mol Cancer Ther 12 2013 2342 2355
27. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
28. B.S. Carver, J. Tran, and A. Gopalan Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat Genet 41 2009 619 624
29. M. Yoshimoto, A.M. Joshua, and I.W. Cunha Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome Mod Pathol 21 2008 1451 1460
30. A. Krohn, T. Diedler, and L. Burkhardt Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer Am J Pathol 181 2012 401 412